Etoposide and carbo‐or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: A large retrospective study. Issue 1 (22nd September 2014)

• Record Type: Journal Article
• Authors: van Maldegem, Annemiek M.; Benson, Charlotte; Rutkowski, Piotr; Blay, Jean‐Yves; van den Berg, Henk; Placzke, Joanna; Rasper, Meybrit; Judson, Ian; Juergens, Heribert; Dirksen, Uta; Gelderblom, Hans
• Is Part Of: Pediatric blood & cancer. Volume 62:Issue 1(2015:Jan.)
• Page Start: 40
• Page End: 44
• Publication Date: 2014-09-22
• Subjects: Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.25230
• Languages: English
• ISSNs: 1545-5009

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="pbc25230-sec-0001" sec-type="section"> <title>Background</title> <p>Patients with Ewing sarcoma (EWS) who develop refractory or relapsed disease have limited treatment options. In some sarcoma centres in Europe the combination of etoposide with carbo‐ or cisplatin is being used for these patients, however, there are no published data available yet. Here we investigated the outcome of the combination treatment for patients with advanced Ewing sarcoma in progression after standard treatment.</p> </sec> <sec id="pbc25230-sec-0002" sec-type="section"> <title>Procedure</title> <p>All patients diagnosed with EWS between 1980 and 2012 in one of six major sarcoma centres in Europe and treated with either carboplatin and etoposide or cisplatin and etoposide were included and data were retrospectively collected for analysis.</p> </sec> <sec id="pbc25230-sec-0003" sec-type="section"> <title>Results</title> <p>A total of 107 patients enrolled in this study of which 61 received the combination of etoposide and carboplatin and 46 received etoposide and cisplatin. The median overall survival (OS) was 23 months for both patient groups and the 5‐year OS was 24.5% for the patients who received carboplatin and etoposide and 20% for those who received cisplatin and etoposide. The progression free survival was better in patients treated with the combination of carboplatin and etoposide (14.5 vs. 6.3 months <italic>P</italic> = 0.023).</p> </sec> <sec id="pbc25230-sec-0004" sec-type="section"> <title>Conclusion</title> <p>This is a retrospective study on the combination treatment of etoposide and carbo‐ or cisplatin in refractory Ewing sarcoma. The results justify exploring the combination in a prospective study with relapsed patients. Pediatr Blood Cancer 2015;62:40–44. © 2014 Wiley Periodicals, Inc.</p> </sec> </abstract>